Efficacy and Safety of 1 % Terbinafine Film-Forming Solution in Chinese Patients with Tinea Pedis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study by Ruo Yu Li et al.
ORIGINAL RESEARCH ARTICLE
Efficacy and Safety of 1 % Terbinafine Film-Forming Solution
in Chinese Patients with Tinea Pedis: A Randomized, Double-
Blind, Placebo-Controlled, Multicenter, Parallel-Group Study
Ruo Yu Li • A. P. Wang • J. H. Xu • L. Y. Xi •
M. H. Fu • M. Zhu • M. L. Xu • X. Q. Li •
W. Lai • W. D. Liu • X. Y. Lu • Z. Q. Gong
Published online: 30 January 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Background and objectives Superficial fungal skin
infections are treated using topical antifungals. The aim of
this study was to demonstrate the efficacy of a single
application of 1 % terbinafine film-forming solution (FFS)
versus placebo for the treatment of tinea pedis in the
Chinese population.
Methods Six centers in China randomized 290 patients in
a 1:1 ratio to receive either 1 % terbinafine FFS or FFS
vehicle (placebo) once on the affected foot/feet. Efficacy
assessments included microscopy and mycologic culture,
and assessing clinical signs and symptoms at baseline, and
at weeks 1 and 6 after the topical treatment. All adverse
events were recorded.
Results At week 6, 1 % terbinafine FFS was superior to
placebo for effective treatment rate (63 vs. 8 %); clinical
cure (30 vs. 6 %); mycological cure (86 vs. 12 %); nega-
tive microscopy (90 vs. 24 %); and negative mycological
culture (90 vs. 27 %): all p B 0.001 and clinically relevant.
At week 6, 1 % terbinafine FFS was clinically superior to
placebo for the absence of: erythema (69 vs. 29 %); des-
quamation (33 vs. 8 %); and pruritus (70 vs. 30 %): all
p B 0.001 and clinically relevant. At week 6, differences in
the average total signs and symptoms scores were signifi-
cantly lower for 1 % terbinafine FFS versus placebo
(p B 0.001). Both 1 % terbinafine FFS and placebo were
safe and well tolerated based on adverse events and
investigator and patient assessments.
Conclusions This double-blind, randomized, multicenter
study demonstrated one single topical application of 1 %
terbinafine FFS was safe and effective in the treatment of
tinea pedis in the Chinese population.
1 Introduction
Tinea pedis (athlete’s foot) is becoming increasingly pre-
valent worldwide because of various factors including
changes in lifestyle and incidence of various diseases. Its
prevalence is now more than 50 % of the population in
Northern and Central Europe, approximately 25 % in the
Mediterranean, and 28 % in Singapore; an incidence of
39 % has also been reported in North Western China [1–3].
Tinea pedis is generally treated with the topical appli-
cation of various antifungal creams, gels, sprays, liquids,
and powders. Topical terbinafine has been highly suc-
cessful in treating tinea pedis. A single application of 1 %
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terbinafine film forming solution (FFS) has been shown to
be as safe, and superior in efficacy, to placebo in a multi-
center European study in tinea pedis. The relapse/re-
infection rate after 3 months was similar to that using 1 %
terbinafine cream for 7 days [4].
One percent terbinafine FFS is an alcohol solvent for-
mulation that evaporates upon application to the skin,
leaving a smooth, almost invisible film that delivers ter-
binafine to the skin. After a single application, high levels
of 1 % terbinafine penetrate the stratum corneum where
dermatophytes are located and fungicidal levels of terbi-
nafine remain there for up to 13 days [5].
Here, we report the results of a randomized, double-
blind, placebo-controlled, multicenter, parallel-group study
of the efficacy and safety of 1 % terbinafine FFS in Chi-
nese patients with tinea pedis.
2 Patients and Methods
2.1 Patients
This was a randomized, double-blind, placebo-controlled,
multicenter, parallel-group study conducted at six investi-
gational centers in China. Ethical committee approval was
obtained at each study center. Patients who were consulted
for tinea pedis infection in the study centers were questioned
regarding their tinea pedis history and their eligibility was
confirmed against the following inclusion criteria: male or
female individual aged C18 years with clinical tinea pedis
infection (lesions between the toes with possible extension
to lateral borders of foot and sole), total signs and symptoms
score C3, and positive microscopy [potassium hydroxide
(KOH) wet mount] from the target foot prior to one single
topical treatment. Patients with positive microscopy at
baseline were to be considered as a delayed exclusion if the
result of the culture of the mycologic sample taken at the
baseline visit was negative (or positive, but not for a der-
matophyte). Only patients who were able to provide written,
informed consent were included in the study. The study was
registered on the Clinicaltrials.gov website (registration
number: NCT01433107).
The planned number of patients was 286, randomized in
a 1:1 ratio to receive one single dose of either 1 % terbi-
nafine FFS or FFS vehicle (placebo) applied to the affected
foot (or feet) on day 1.
2.2 Randomization
A randomization list was produced by using a validated
system that automates the random assignment of treatment
to randomization numbers. At the randomization/treatment
visit (day 1), each subject who fulfilled all the inclusion/
exclusion criteria was given the lowest available number
on the randomization list available at the study site. This
number assigned them to one of the two treatment arms.
2.3 Treatment Blinding
Subjects, investigator staff, persons performing the
assessments, study monitors, and data analysts were blin-
ded to the identity of the treatment from the time of ran-
domization until database lock. This was achieved by
keeping randomization data strictly confidential until the
time of unblinding, and by the use of study treatments that
were all identical in packaging, labeling, schedule of
administration, appearance, and odor.
2.4 Study Visits
Follow-up visits to the study center took place 1 and
6 weeks after treatment. Even if both feet were infected,
only one foot was to be assessed for efficacy (the target
foot). The study was completed when all patients com-
pleted all visits up to the week-6 final visit and when all
mycologic evaluations up to the week-6 visit were avail-
able. Adverse events (AEs) were collected throughout the
study.
2.5 Assessments
Mycologic samples were taken at baseline and at weeks 1
and 6 and assessed by microscopy (KOH wet mount) and
by culture. Mycologic samples were taken from inter-dig-
ital lesions with the most severe signs and symptoms of
disease and pooled for KOH wet mount examination and
culture. Mycologic cure was defined by negative KOH
microscopy and negative mycologic culture. Clinical signs
and symptoms scores were assessed at the baseline visit
and at weeks 1 and 6. Clinical signs and symptoms
including desquamation (scaling), erythema, pruritus,
incrustation (crusting), pustules, and vesiculation were
evaluated by the investigator and recorded at every visit
using a 4-point scale (0 = absent, 1 = mild, 2 = moder-
ate, 3 = severe). Clinical cure was defined as all assess-
ments of signs and symptoms scored as absent. Complete
cure was defined as both mycologic cure and clinical cure.
2.6 Study Objectives
The primary efficacy variable was the rate of effective
treatment at week 6, using the following definition:
mycologic cure and total sum of signs and symptoms
score B2, provided that individual severity scores for
incrustation, pustules, and vesiculation were absent (0), and
individual severity scores for desquamation, erythema, and
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pruritus were absent or mild (B1). The secondary objec-
tives were to evaluate the safety profile of 1 % terbinafine
FFS; mycologic cure rate at weeks 1 and 6 and effective
treatment rate at week 1.
At weeks 1 and 6, the investigator assessed efficacy and
safety of the treatments. The patients assessed local toler-
ability at week 6, on a 5-point scale (very good, good,
moderate, poor, and very poor). If both feet were treated,
both feet were to be assessed equally for safety.
2.7 Statistical Analysis
The intent-to-treat analysis set (ITT) was defined as all
randomized patients regardless of whether or not they had
been treated and regardless if they were delayed exclu-
sions or not. A full analysis set (FAS) was also defined,
which included all randomized patients who had been
treated and who were not delayed exclusions. In both ITT
and FAS, patients with missing mycology results or
missing clinical signs and symptoms scores were treated
as ‘‘failure’’ in the analysis of the main efficacy variable.
The per-protocol set (PPS) was defined as patients
included in the FAS, who provided efficacy results at
week 6 and who had no major protocol violation that
could impact the efficacy evaluation. Efficacy analysis
was conducted on the ITT, FAS, and PPS populations,
and analysis of the FAS was considered the primary
efficacy analysis.
The two treatment groups were compared with respect
to the effective treatment rate using the Cochran–Mantel–
Haenszel (CMH) test of general association stratified by
centers. A supportive analysis was completed using a
logistic regression model fitted to compare the effective
treatment rate between the two treatment groups. The
influence of the following covariates was explored prior to
including the treatment effect in the model: total signs and
symptoms score at baseline, type of dermatophytes at
baseline, and extension to sole or lateral side and center.
The odds ratio and 95 % confidence interval for the treat-
ment effect was tabulated. Secondary endpoints defined as
rates (clinical cure, mycologic cure, and complete cure
rates) were analyzed similarly to the primary efficacy
endpoint analysis.
Individual clinical signs and symptoms scores were
summarized by treatment group. Differences between
treatment groups were analyzed using a CMH test with
rank scores, stratified by center and baseline level. The
total clinical signs and symptoms score was treated as a
continuous variable and summarized appropriately. Dif-
ferences between treatment groups were analyzed using an
analysis of covariance with center and baseline score as a




The baseline demographic and disease characteristics of
the two treatment groups were similar (Table 1). A total of
290 patients were enrolled and randomized, 145 each to
1 % terbinafine FFS and placebo, of which 246 patients
(85 %) completed the study, and 44 patients (15 % in total,
19 % in the 1 % terbinafine FFS group, and 12 % in the
placebo group) discontinued from the study prior to week
6. The primary reason for discontinuation was because of
mycologic test procedure results (14 %), i.e., delayed
exclusions that were not followed up until week 6. In
addition, two patients discontinued because of protocol
deviations, one patient discontinued because of withdrawal
of consent, and one patient was lost to follow-up. Because
of the delayed exclusions, 237 patients were included in the
FAS, 115 in the 1 % terbinafine FFS group, and 122 in the
placebo group.
The epidemiologic pattern of disease observed was
representative of a typical tinea pedis population: over
85 % of patients had bilateral lesions and 50 % had lesion
extensions on the sole(s) and/or lateral area(s) of the feet.
Trichophyton rubrum was identified in 68 % of patients
randomized in each of the treatment groups, followed by
Trichophyton mentagrophytes, which was prevalent in
11 % of the 1 % terbinafine FFS randomized patients and
in 17 % of the placebo randomized patients. The median
duration of current tinea pedis was around 12 weeks. Prior
to the study the patients had an average of three episodes
per year. These previous episodes were moderate to severe
for more than 75 % of the patients.
3.2 Treatment Follow-Up at Week 6
Figure 1 illustrates the results of treatment at week 6. At
Week 6, over 63 %, 86 %, and 30 %, of patients in the 1 %
terbinafine FFS group experienced effective treatment,
mycologic cure, and clinical cure, respectively, compared
with 8 %, 12 %, and 6 %, in the placebo group, respec-
tively. All three differences were statistically significant
(p \ 0.001) and clinically relevant. The superiority of 1 %
terbinafine FFS over placebo shown in the primary efficacy
analysis conducted on the FAS population was confirmed
both in the ITT and PPS populations.
3.3 Mycologic Evaluations at Weeks 1 and 6
At week 1, a total of 49 % and 81 % of patients in the 1 %
terbinafine FFS group experienced negative microscopy and
negative mycologic culture, respectively, compared with 26
% and 24 % in the placebo group, respectively. Both
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differences were statistically significant (p \ 0.001) and
clinically relevant. However, over time, 1 % terbinafine FFS
was even more effective than placebo. At week 6, a total of
90 % and 90 % of patients in the 1 % terbinafine FFS group
experienced negative microscopy and negative mycological
culture, respectively, compared with 24 % and 27 % in the
placebo group, respectively. Both differences were statisti-
cally significant (p \ 0.001) and clinically relevant.
Although the same proportion in the 1 % terbinafine
FFS group experienced negative microscopy and negative
Table 1 Patient and disease characteristics
Characteristic/statistic/category 1 % terbinafine FFS (n = 145) Placebo (n = 145) Total (n = 290)
Age (years)
Mean ± SD 35.27 ± 12.805 34.05 ± 11.936 34.66 ± 12.372
Range 18.5–82.3 18.6–84.1 18.5–84.1
Sex, n (%)
Male 95 (65.5) 99 (68.3) 194 (66.9)
Female 50 (34.5) 46 (31.7) 96 (33.1)
Sites of tinea pedis lesion, n (%)
Unilateral 23 (15.9) 17 (11.7) 40 (13.8)
Bilateral 122 (84.1) 128 (88.3) 250 (86.2)
Inter-digital space (s) only, n (%) 72 (49.7) 71 (49.0) 143 (49.3)
Extension to sole/lateral surfaces, n (%) 73 (50.3) 74 (51.0) 147 (50.7)
Positive for dermatophyte 115 (79.3) 122 (84.1) 237 (81.7)
Species identified on culture (all collection areas), n (%)
Trichophyton rubrum 98 (67.6) 98 (67.6) 196 (67.6)
Trichophyton mentagrophytes 16 (11.0) 25 (17.2) 41 (14.1)
Trichophyton tonsurans 0 (0) 0 (0) 0 (0)
Epidermophyton floccosum 1 (0.7) 0 (0) 1 (0.3)
Duration of current tinea pedis episode (weeks), n (%)
Number of patients 137 142 279
Mean ± SD 17.65 ± 21.487 20.67 ± 43.707 19.19 ± 34.598
Range 0.4–176.0 0.1–487.3 0.1–487.3
\2 13 (9.0) 13 (9.0) 26 (9.0)
2–\4 14 (9.7) 20 (13.8) 34 (11.7)
4–\8 25 (17.2) 18 (12.4) 43 (14.8)
8–\26 54 (37.2) 59 (40.7) 113 (39.0)
26–\52 26 (17.9) 24 (16.6) 50 (17.2)
C52 7 (4.8) 9 (6.2) 16 (5.5)
Missing 6 (4.1) 2 (1.4) 8 (2.8)
Average number of tinea pedis episodes per year
Number of patients 145 145 290
Mean ± SD 3.3 ± 3.15 3.0 ± 2.55 3.2 ± 2.87
Range 0–20 0–15 0–20
Severity of tinea pedis, n (%)
Mild 19 (13.1) 19 (13.1) 38 (13.1)
Moderate 62 (42.8) 78 (53.8) 140 (48.3)
Severe 48 (33.1) 35 (24.1) 83 (28.6)
Missing 16 (11.0) 13 (9.0) 29 (10.0)
Tinea pedis episodes responsive to systemic or topical antifungal drugs, n (%)
No 0 (0) 0 (0) 0 (0)
Yes 105 (72.4) 110 (75.9) 215 (74.1)
Missing 40 (27.6) 35 (24.1) 75 (25.9)
SD standard deviation
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mycologic culture, there was not a complete match of these
results in the same subjects. That is to say that some sub-
jects experienced negative microscopy but positive myco-
logic culture and vice versa. In general, mycologic culture
results did match the direct microscopy results and there
were fewer discrepancies in the terbinafine group (93 %
matching) than in the placebo group (73.8 %). The small
discrepancy in the terbinafine group reduced the mycologic
cure rate to 86 %.
3.4 Summary of Clinical Signs and Symptoms
at Weeks 1 and 6
Erythema, desquamation, and pruritus were the most fre-
quent signs and symptoms at baseline. They were all
present in more than 90 % of the patients in each treatment
group at baseline.
Figure 2 illustrates the signs and symptoms scores of
erythema characteristics at baseline, and weeks 1 and 6. At
baseline and week 1, the percentage of patients with mild,
moderate, and severe ratings of erythema was similar
between both treatment groups. However, over time, 1 %
terbinafine FFS was more effective than placebo. At week
6, 69 % of patients reported absence of erythema, com-
pared with only 29 % in the placebo group. This difference
was statistically significant (p \ 0.001). Interestingly, at
week 6, only 1 % of patients reported severe erythema in
the 1 % terbinafine FFS group, compared with 7 % in the
placebo group.
Figure 3 illustrates the signs and symptoms scores of
desquamation characteristics at baseline, and at weeks 1
and 6. At baseline, all patients experienced desquamation
and the percentage of patients with mild, moderate, and
severe ratings of desquamation was similar between both
treatment groups, with the majority of patients experienc-
ing severe or moderate desquamation (in 99 % and 95 % of
patients in the 1 % terbinafine FFS and placebo groups,
respectively). At week 1, the majority of patients still
experienced desquamation and the percentage of patients
with mild, moderate, and severe ratings of desquamation
was again similar between both treatment groups. How-
ever, over time, 1 % terbinafine FFS was more effective
than placebo. At week 6, 33 % of patients reported absence
of desquamation in the 1 % terbinafine FFS group, com-
pared with only 8 % in the placebo group and the des-
quamation observed was mild in the 1 % terbinafine FFS
Fig. 1 Summary of treatment results at week 6, of 1 % terbinafine
film-forming solution (FFS) versus placebo, assessed by effective
treatment, mycologic cure, and clinical cure (full analysis set)
Fig. 2 Signs and symptoms scores of erythema at baseline and at
weeks 1 and 6, of 1 % terbinafine film-forming solution (FFS) versus
placebo (full analysis set). p \ 0.001 week 6 versus baseline
Fig. 3 Signs and symptoms scores of desquamation at baseline and at
weeks 1 and 6, of 1 % terbinafine film-forming solution (FFS) versus
placebo (full analysis set). p \ 0.001 week 6 versus baseline
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group, whereas it was still moderate to severe in the pla-
cebo group. Interestingly, at week 6, only 6 % of patients
reported severe desquamation in the 1 % terbinafine FFS
group, compared with 34 % in the placebo group. The
difference in desquamation severity was statistically sig-
nificant (p \ 0.001).
Figure 4 illustrates the signs and symptoms scores of
pruritus characteristics at baseline, and at weeks 1 and 6. At
baseline, the percentage of patients with mild, moderate,
and severe ratings of pruritus was similar between both
treatment groups, with the majority of patients experienc-
ing severe or moderate pruritus (in 85 % and 84 % of
patients in the 1 % terbinafine FFS and placebo groups,
respectively). However, over time, 1 % terbinafine FFS
was significantly more effective than placebo. At week 1,
about 60 % of the patients still experienced pruritus;
however, the percentage of patients reporting moderate to
severe pruritus was almost twice that in the placebo group
compared with the 1 % terbinafine FFS group (19 vs.
34 %). At Week 6, 70 % of patients reported absence of
pruritus in the 1 % terbinafine FFS group, compared with
only 30 % in the placebo group. Mild and moderate pru-
ritus was observed in 25 % and 3 % of patients in the 1 %
terbinafine group FFS, respectively, compared with 38 %
and 21 % in the placebo group, respectively. Interestingly,
at week 6, no patients reported severe pruritus in the 1 %
terbinafine FFS group, compared with 13 patients (11 %)
in the placebo group. The difference in pruritus severity
was statistically significant (p \ 0.001).
At week 1, the average total signs and symptoms scores
were similar; 4.2 in 114 patients in the 1 % terbinafine FFS
group and 4.8 in 122 patients in the placebo group; but the
difference nevertheless was statistically significant
(p = 0.005). At week 6, the average signs and symptoms
score for 1 % terbinafine FFS was much lower compared
with placebo; 1.6 in 113 patients versus 4.7 in 121 patients,
respectively. This difference was again statistically sig-
nificant (p \ 0.001).
The investigator global assessment of efficacy at week 6
was rated very good or good in 81 % of patients in the 1 %
terbinafine FFS group, compared with 25 % in the placebo
group.
3.5 Safety
A total of 20 patients experienced at least one AE in the
study; 9 in the 1 % terbinafine FFS group and 11 in the
placebo group. A total of 30 AEs were reported; 14 AEs in
the 1 % terbinafine FFS group and 16 AEs in the placebo
group. All AEs were mild or moderate in severity. A total
of 26 AEs were suspected to be related to study treatment;
13 AEs each in the 1 % terbinafine FFS and placebo group.
The most frequently reported AEs were application-site
pain in six patients (4 %) each in the two treatment groups,
and application-site pruritus in three patients (2 %) in the
placebo group.
In addition, investigators’ assessments of safety were
similar between the two treatment groups; investigators
rated the safety as very good or good, in 97 % of patients in
the 1 % terbinafine FFS group and 99 % in the placebo
group. Furthermore, patient assessment of local tolerability
was also rated similar between the two treatment groups for
very good or good, in 95 % of patients in the 1 % terbi-
nafine FFS group and 92 % in the placebo group.
4 Discussion
This multicenter study demonstrated a single application of
1 % terbinafine FFS to be statistically and clinically more
efficacious than placebo in the treatment of tinea pedis in a
Chinese population. The 1 % terbinafine FFS was safe and
well tolerated by over 90 % of the patients.
The results of this study mirror those of a similar study
carried out in European patients [4], although in the current
study patients had a disease severity (total signs and
symptoms at baseline/plantar involvement) much greater
than in the European phase III study. The baseline average
signs and symptoms score was three times higher in the
Chinese population and plantar involvement much more
common (in many cases extending onto the lateral aspect
of the soles). In addition, the placebo response in this study
was much lower than in the European study (8 vs. 17 %).
Extension of tinea pedis to the lateral surfaces of the foot is
often an indication of chronic infection and associated with
greater disease severity. The severe disease in the Chinese
Fig. 4 Signs and symptoms scores of pruritus at baseline and at
weeks 1 and 6, of 1 % terbinafine film-forming solution (FFS) versus
placebo (full analysis set). p \ 0.001 week 6 versus baseline
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population could possibly also explain the low placebo
response for effective treatment at week 6. Statistically
significant differences were recorded in patients treated
with 1 % terbinafine FFS compared with placebo for
effective treatment, mycological cure, clinical cure, nega-
tive microscopy, and negative mycological culture.
As seen previously, T. rubrum predominated, followed
by T. mentagrophytes [4, 6]. Clinical signs and symptoms
scores were lower for patients in the 1 % terbinafine FFS
group compared with placebo at both weeks 1 and 6. The
proportion of patients exhibiting mild, moderate, and
severe erythema, desquamation, and pruritus decreased
during the study in those treated with 1 % terbinafine FFS,
through week 1 to week 6, compared with placebo. Dif-
ferences in the average total signs and symptoms scores
were significantly lower for 1 % terbinafine FFS than
placebo at weeks 1 and 6. Moreover, the higher ratings of
1 % terbinafine FFS in the investigator assessments of
efficacy at week 6 in comparison with placebo further
highlighted the superiority of 1 % terbinafine FFS over
placebo.
The rate of delayed exclusions because of positive
microscopy with negative culture (14 %) was similar to
that in the European study (16 %) [4], demonstrating the
experience of the investigators in diagnosing tinea pedis
and the effectiveness of the mycology laboratories.
As reported previously [4], 1 % terbinafine FFS is safe
and well tolerated. The occurrence of AEs in this study was
low, and all were mild and moderate in nature and did not
give rise to any new safety concerns about 1 % terbina-
fine FFS. Investigator assessment of safety and patient
assessment of local tolerability were rated very good or
good in more than 90 % of patients in the 1 % terbinafine
FFS group and the placebo group, indicating no safety or
tolerability concerns.
The proportion of patients with missing data for each of
the reported parameters was very low. The ease of a single-
dose application encourages those with athlete’s foot to be
treated and virtually eliminates noncompliance, which is
known to be widespread [7]. Half of the respondents in a
consumer survey [8] reported using antifungal treatments
for less than 13 days, despite most antifungals requiring
3–4 weeks of therapy. In addition, the survey respondents
had experienced tinea pedis for an average of 7 years and
64 % experienced more than four episodes a year. This
may partly be because of the prevalence of fungal spores
but possibly owing to incomplete eradication of the fungus
by their lack of compliance with conventional multi-dose
treatments. The current study shows that even with a fun-
gicidal treatment that quickly achieves high levels of active
ingredient in the stratum corneum, the effect increases with
time, indicating that contact between the agent and the
fungus needs to be maintained.
As well as waning interest in prolonged topical anti-
fungal treatments, patients may also erroneously interpret
relief of signs and symptoms as indicating eradication of
the fungus. It is well known that fungal elements may be
present in the skin without causing signs or symptoms [9,
10]. Application of antifungal treatment to the whole of the
foot will treat both symptomatic and non-symptomatic
areas. Hay et al. concluded that this is more likely to be
undertaken by patients using terbinafine 1 % FFS com-
pared with multi-dose treatments [11].
Furthermore in relation to compliance, a meta-analysis
found terbinafine 1 % FFS to be non-inferior to other an-
tifungals when used for many weeks of treatment. The data
for terbinafine 1 % FFS were compared with trials of az-
oles and even other allylamines (butenafine and naftifine)
versus vehicle, used for several weeks. Single treatment
with terbinafine was found to be superior to some azoles
(clotrimazole and oxiconazole) [12].
5 Conclusion
This study confirms that 1 % terbinafine FFS, applied as a
single dose, is a highly effective, safe, and convenient
treatment for tinea pedis in a Chinese population. The
incentive to comply with this one-time treatment method is
likely to have benefits for both patients and public health in
general.
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